U.S. Markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.37 (-1.58%)
     
  • Nasdaq

    14,030.38
    -130.97 (-0.92%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.50
    +0.46 (+0.65%)
     
  • Gold

    1,763.90
    -10.90 (-0.61%)
     
  • Silver

    25.84
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1865
    -0.0045 (-0.3797%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • Vix

    20.70
    +2.95 (+16.62%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.8272%)
     
  • USD/JPY

    110.1500
    -0.0810 (-0.0735%)
     
  • BTC-USD

    35,568.39
    -2,150.62 (-5.70%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Coronavirus J&J vaccine concerns 'are very, very tiny risks worth taking': Yale doctor

·Anchor
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are recommending a "pause" in the use of Johnson & Johnson's COVID-19 vaccine to review blood clot cases, sparking anxiety and concern among those who have received or are scheduled to receive the vaccine.

Dr. David Katz, a preventive medicine specialist who founded and served as director of Yale University’s Yale-Griffin Prevention Research Center from 1998 to 2019, cautioned that while we have to take this development seriously, there is "always some risk" when it comes to medicine.

“One of the critical things we need to realize is that everything we do in medicine comes with some risk," Katz told Yahoo Finance. “If the risk related to a vaccine is one in a million, but your risk of getting [COVID-19] is massively higher… those are very, very tiny risks worth taking.”

According to Katz, the potential for these adverse events to occur appear to be "a very remote probability."

In a joint statement on Tuesday, the CDC and FDA said that out of more than 6.8 million doses of the J&J (JNJ) vaccine that have been administered, there were six reports, including one death, of a rare and severe type of blood clot in individuals after receiving the vaccine.

ORLANDO, FLORIDA, UNITED STATES - 2021/04/10: Johnson & Johnson COVID-19 vaccine boxes are seen at a vaccination site.
Doses of the Johnson & Johnson vaccine are being administered throughout the state of Florida despite a small number of patients who have experienced adverse reactions, including blood clots. (Photo by Paul Hennessy/SOPA Images/LightRocket via Getty Images)
ORLANDO, FLORIDA, UNITED STATES - 2021/04/10: Johnson & Johnson COVID-19 vaccine boxes are seen at a vaccination site. (Photo by Paul Hennessy/SOPA Images/LightRocket via Getty Images)

J&J pause ‘makes sense’

More than two dozen states suspended the usage of J&J’s vaccine after the FDA and CDC recommended the pause "out of an abundance of caution." Several pharmacies also followed suit. 

“We now have information about a potential risk we didn’t have before so we have to take that seriously. I think the pause makes sense,” said Katz. “If you are scheduled for the J&J vaccine, then I would wait and let the dust settle. Either opt for one of the other vaccines or wait until there is a full investigation and there is a change in the recommendations regarding this particular vaccine.”

The suspension of J&J’s vaccine complicates the country’s vaccine campaign, although health officials assure it won’t significantly disrupt vaccination efforts nationwide since the bulk of the U.S. vaccine supply is Pfizer (PFE) and Moderna (MRNA).

This content is not available due to your privacy preferences.
Update your settings here to see it.

In a statement, White House COVID-19 Response Coordinator Jeff Zients said the U.S. is still on track to reach President Biden’s goal of 200 million doses by his 100th day in office, while noting that J&J’s vaccine makes up less than 5% of the doses administered.

The vaccination rate nationwide is exceeding 3 million doses a day, well above initial predictions. More than a third of the country has received at least one dose of a vaccine, according to the CDC, while 75 million, or 22%, of the population is fully vaccinated.

Seana Smith anchors Yahoo Finance Live’s 3-5 p.m. ET program. Follow her on Twitter @SeanaNSmith

READ MORE: